• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply.

作者信息

Brandman Danielle, Boyle Marie, McPherson Stuart, Van Natta Mark L, Sanyal Arun J, Kowdley Kris, Neuschwander-Tetri Brent, Chalasani Naga, Abdelmalek Manal F, Terrault Norah A, McCullough Art, Bettencourt Ricki, Caussy Cyrielle, Kleiner David E, Behling Cynthia, Tonascia James, Anstee Quentin M, Loomba Rohit

机构信息

Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.

Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.

出版信息

Aliment Pharmacol Ther. 2022 Jul;56(1):182-183. doi: 10.1111/apt.16972.

DOI:10.1111/apt.16972
PMID:35689309
Abstract
摘要

相似文献

1
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD-not everyone fits the mould. Authors' reply.
Aliment Pharmacol Ther. 2022 Jul;56(1):182-183. doi: 10.1111/apt.16972.
2
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD - not everyone fits the mould.信函：非侵入性预测模型用于排除非酒精性脂肪性肝病中的肝硬化——并非所有人都符合模式。
Aliment Pharmacol Ther. 2022 Jul;56(1):180-181. doi: 10.1111/apt.16931.
3
Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors' reply.信件：非酒精性脂肪性肝病中伴有显著肝纤维化患者的冠状动脉粥样硬化——无创检测领域。作者回复
Aliment Pharmacol Ther. 2021 Jul;54(2):216. doi: 10.1111/apt.16462.
4
Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' reply.
Aliment Pharmacol Ther. 2023 Jun;57(12):1463-1464. doi: 10.1111/apt.17517.
5
Editorial: screening for hepatocellular carcinoma in NAFLD cirrhosis-towards abbreviated MRI alternative in patients with obesity? Authors' reply.社论：非酒精性脂肪性肝病肝硬化患者肝细胞癌的筛查——肥胖患者是否采用简化磁共振成像替代方案？作者回复。
Aliment Pharmacol Ther. 2022 May;55(9):1212-1213. doi: 10.1111/apt.16908.
6
Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
J Hepatol. 2020 Aug;73(2):466-467. doi: 10.1016/j.jhep.2020.04.020. Epub 2020 May 15.
7
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).比较非酒精性脂肪性肝病 (NAFLD) 中用于排除肝硬化的临床预测规则。
Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17.
8
Letter: should we abandon FIB-4 to characterise noninvasively patients with NAFLD? Authors' reply.信函：我们是否应该摒弃FIB-4来对非酒精性脂肪性肝病患者进行无创性特征描述？作者回复。
Aliment Pharmacol Ther. 2023 Apr;57(8):922-923. doi: 10.1111/apt.17448.
9
ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.ADAMTSL2 蛋白和可溶性生物标志物特征可识别非酒精性脂肪性肝病成人的非酒精性脂肪性肝炎和纤维化高危人群。
J Hepatol. 2022 Jan;76(1):25-33. doi: 10.1016/j.jhep.2021.09.026. Epub 2021 Oct 1.
10
Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.系统评价和荟萃分析：肥胖患者非酒精性脂肪性肝病相关纤维化的无创性检测。
Obes Rev. 2018 Feb;19(2):281-294. doi: 10.1111/obr.12628. Epub 2017 Nov 9.